S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The "King Of Quants" sees 10X potential... (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The "King Of Quants" sees 10X potential... (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The "King Of Quants" sees 10X potential... (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The "King Of Quants" sees 10X potential... (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The "King Of Quants" sees 10X potential... (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The "King Of Quants" sees 10X potential... (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Modern Day Options Trading For Beginners! (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The "King Of Quants" sees 10X potential... (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The "King Of Quants" sees 10X potential... (Ad)
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
NASDAQ:GRTX

Galera Therapeutics - GRTX Stock Forecast, Price & News

$2.13
-0.06 (-2.74%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.11
▼
$2.30
50-Day Range
$1.59
▼
$2.47
52-Week Range
$1.12
▼
$2.75
Volume
544,764 shs
Average Volume
860,073 shs
Market Capitalization
$91.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75

Galera Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
310.8% Upside
$8.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of Galera Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$212,350 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.56) to ($1.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

656th out of 983 stocks

Pharmaceutical Preparations Industry

314th out of 478 stocks

See Top Rated MarketRank™ Stocks Here

GRTX stock logo

About Galera Therapeutics (NASDAQ:GRTX) Stock

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRTX Stock News Headlines

March 22, 2023 | americanbankingnews.com
Insider Buying: Galera Therapeutics, Inc. (NASDAQ:GRTX) Insider Acquires 11,000 Shares of Stock
March 16, 2023 | americanbankingnews.com
Mel Sorensen Purchases 100,000 Shares of Galera Therapeutics, Inc. (NASDAQ:GRTX) Stock
March 22, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
March 15, 2023 | americanbankingnews.com
Galera Therapeutics, Inc. (NASDAQ:GRTX) CFO Chris Degnan Buys 10,000 Shares
March 10, 2023 | finance.yahoo.com
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
March 8, 2023 | finance.yahoo.com
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
March 8, 2023 | finanznachrichten.de
Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
March 8, 2023 | finance.yahoo.com
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
March 22, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
March 2, 2023 | benzinga.com
Galera Therapeutics Chief Financial Officer Awarded $331K Worth of Stock Options
March 1, 2023 | benzinga.com
Galera Therapeutics Chief Operating Officer Awarded $241K Worth of Stock Options
March 1, 2023 | benzinga.com
President and CEO at Galera Therapeutics Acquires Company Stock Options Worth 440,000 Shares
March 1, 2023 | benzinga.com
Galera Therapeutics Chief Commercial Officer Awarded $241K Worth of Stock Options
February 23, 2023 | 247wallst.com
Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation
February 15, 2023 | finance.yahoo.com
Galera Therapeutics expects to raise $30M from direct stock offering
February 15, 2023 | marketwatch.com
Galera Therapeutics Shares Rise Premarket on FDA Priority Review >GRTX
February 15, 2023 | finance.yahoo.com
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
February 15, 2023 | finance.yahoo.com
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
December 12, 2022 | finance.yahoo.com
Malvern-based Galera shares rise on FDA filing for lead cancer therapy drug
December 12, 2022 | finance.yahoo.com
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
November 22, 2022 | finance.yahoo.com
Galera to Present at Piper Sandler Annual Healthcare Conference
November 9, 2022 | finanznachrichten.de
Galera Therapeutics: Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
November 9, 2022 | finance.yahoo.com
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
November 7, 2022 | finance.yahoo.com
One Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous year
November 1, 2022 | finance.yahoo.com
Galera Therapeutics' Avasopasem Reduces Chemo-Related Kidney Disease By 50% Versus Placebo At One-Year
October 26, 2022 | finance.yahoo.com
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
September 26, 2022 | finance.yahoo.com
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
See More Headlines
Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GRTX Company Calendar

Last Earnings
11/10/2021
Today
3/21/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRTX
CUSIP
N/A
CIK
1563577
Web
www.galeratx.com
Phone
610-725-1500
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+310.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,220,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-109.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.88
Quick Ratio
2.88

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.83) per share
Price / Book
-0.56

Miscellaneous

Outstanding Shares
42,830,000
Free Float
39,147,000
Market Cap
$91.23 million
Optionable
Not Optionable
Beta
1.75

Key Executives

  • Dr. J. Mel Sorensen M.D. (Age 65)
    CEO, Pres & Director
    Comp: $820.77k
  • Mr. Christopher Degnan (Age 42)
    Chief Financial Officer
    Comp: $529.35k
  • Mr. Mark J. Bachleda M.B.A. (Age 47)
    Pharm.D., Chief Commercial Officer
    Comp: $476.5k
  • Dr. Robert A. Beardsley M.B.A. (Age 60)
    Ph.D., Co-Founder & COO
  • Dr. Dennis P. Riley Ph.D.
    Chief Scientific Officer, Emeritus
  • Ms. Jennifer Evans Stacey Esq. (Age 57)
    Chief Legal & Compliance Officer and Sec.
  • Dr. Jon T. Holmlund M.D. (Age 65)
    Exec. Officer
  • Ms. Andie Collier
    Sr. VP of Regulatory Affairs
  • Ms. Judy Schnyder
    Sr. VP of Clinical Operations & Data Management
  • Dr. Eugene P. Kennedy F.A.C.S. (Age 53)
    FACS, M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GRTX Stock - Frequently Asked Questions

Should I buy or sell Galera Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTX shares.
View GRTX analyst ratings or view top-rated stocks.

What is Galera Therapeutics' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month target prices for Galera Therapeutics' shares. Their GRTX share price forecasts range from $6.00 to $12.00. On average, they predict the company's stock price to reach $8.75 in the next year. This suggests a possible upside of 310.8% from the stock's current price.
View analysts price targets for GRTX or view top-rated stocks among Wall Street analysts.

How have GRTX shares performed in 2023?

Galera Therapeutics' stock was trading at $1.49 at the beginning of the year. Since then, GRTX shares have increased by 43.0% and is now trading at $2.13.
View the best growth stocks for 2023 here.

When is Galera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our GRTX earnings forecast.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

When did Galera Therapeutics IPO?

(GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager.

What is Galera Therapeutics' stock symbol?

Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX."

Who are Galera Therapeutics' major shareholders?

Galera Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc. (5.85%), Geode Capital Management LLC (0.61%), Renaissance Technologies LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures Ltd Novartis, Chris Degnan, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund, Linda West, Mark Bachleda and Mel Sorensen.
View institutional ownership trends.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galera Therapeutics' stock price today?

One share of GRTX stock can currently be purchased for approximately $2.13.

How much money does Galera Therapeutics make?

Galera Therapeutics (NASDAQ:GRTX) has a market capitalization of $91.23 million. The company earns $-62,220,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How can I contact Galera Therapeutics?

Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The official website for the company is www.galeratx.com. The company can be reached via phone at 610-725-1500 or via email at cdegnan@galeratx.com.

This page (NASDAQ:GRTX) was last updated on 3/22/2023 by MarketBeat.com Staff